BIO vs TERN · rev $2.58B vs $6.12B cap
BIO (BIO) versus Terns Pharmaceuticals Inc (TERN) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Terns Pharmaceuticals Inc (TERN) is a biotechnology company listed on NASDAQ.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
Latest reported TERN revenue for 2022-12-31 was $0. Net income was -$60.3M. TERN currently screens at market cap $6.12B.
BIO currently screens at market cap $0. TERN currently screens at market cap $6.12B.
Not investment advice. Open the BIO and TERN stock pages for the full models.
Not investment advice.